PT0253

PT0253 is a small molecule inhibitor targeting the KRAS G12D mutation, which is commonly found in various advanced solid tumors. The drug is currently being evaluated as a monotherapy in adult patients with KRAS G12D-mutated advanced solid tumors. Its primary mechanism of action involves direct inhibition of the mutant KRAS G12D protein, aiming to block oncogenic signaling pathways that drive tumor growth and survival. PT0253 is administered via intravenous injection and is under development by PAQ Therapeutics. As of now, it has not received regulatory approval and remains in early clinical trials (Phase 1) focused on safety, tolerability, and dose determination[1][2][3].